MXPA06013245A - Tratamiento de enfermedades asociadas con el uso de antibioticos. - Google Patents

Tratamiento de enfermedades asociadas con el uso de antibioticos.

Info

Publication number
MXPA06013245A
MXPA06013245A MXPA06013245A MXPA06013245A MXPA06013245A MX PA06013245 A MXPA06013245 A MX PA06013245A MX PA06013245 A MXPA06013245 A MX PA06013245A MX PA06013245 A MXPA06013245 A MX PA06013245A MX PA06013245 A MXPA06013245 A MX PA06013245A
Authority
MX
Mexico
Prior art keywords
antibiotics
treatment
diseases associated
colitis
resistant
Prior art date
Application number
MXPA06013245A
Other languages
English (en)
Inventor
Youe-Kong Shue
Farah Kondori Babakhani
Franklin W Okumu
Pamela Suzanne Sears
Starr Louise Miller-Shangle
Robert Brian Walsh
Original Assignee
Optimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals Inc filed Critical Optimer Pharmaceuticals Inc
Publication of MXPA06013245A publication Critical patent/MXPA06013245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invencion se refiere al tratamiento o prevencion de enfermedades asociadas con el uso de antibioticos o quimioterapias para el cancer o terapias antivirales, tales como colitis, colitis pseudomembranosa, diarrea asociada a antibioticos e infecciones debidas a especies de C. Difficile, c. Perfringens, Staphylococcus incluyendo Staphylococcus aureus resistente a la meticilina (MRSA) o Enterococcus, incluyendo los enterococos resistentes a la vancomicina (VRE) con el Compuesto I.
MXPA06013245A 2004-05-14 2005-05-13 Tratamiento de enfermedades asociadas con el uso de antibioticos. MXPA06013245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57069704P 2004-05-14 2004-05-14
PCT/US2005/016750 WO2005112990A2 (en) 2004-05-14 2005-05-13 Treatment of diseases associated with the use of antibiotics

Publications (1)

Publication Number Publication Date
MXPA06013245A true MXPA06013245A (es) 2007-05-09

Family

ID=35428857

Family Applications (2)

Application Number Title Priority Date Filing Date
MXPA06013245A MXPA06013245A (es) 2004-05-14 2005-05-13 Tratamiento de enfermedades asociadas con el uso de antibioticos.
MX2014003990A MX344601B (es) 2004-05-14 2005-05-13 Tratamiento de enfermedades asociadas con el uso de antibioticos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2014003990A MX344601B (es) 2004-05-14 2005-05-13 Tratamiento de enfermedades asociadas con el uso de antibioticos.

Country Status (17)

Country Link
US (2) US20070173462A1 (es)
EP (4) EP2305244B1 (es)
JP (2) JP5734545B2 (es)
AT (1) ATE516024T1 (es)
BR (1) BRPI0511119A (es)
CA (2) CA2566687C (es)
CY (2) CY1117501T1 (es)
DK (3) DK2305245T3 (es)
ES (4) ES2395404T3 (es)
HU (3) HUE027757T2 (es)
LT (1) LT2305245T (es)
MX (2) MXPA06013245A (es)
PL (3) PL2305245T3 (es)
PT (2) PT2305244T (es)
SI (2) SI2305245T1 (es)
TR (1) TR201902533T4 (es)
WO (1) WO2005112990A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
EP1848273A4 (en) * 2005-01-31 2010-02-24 Optimer Pharmaceuticals Inc 18-PIECE MACROCYCLES AND ITS ANALOG
CA2626698C (en) * 2005-10-21 2015-12-01 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
WO2009117310A2 (en) * 2008-03-17 2009-09-24 Cedars-Sinai Medical Center Methods for treatment and prevention of mrsa/mssa
EP3144004A1 (en) * 2009-10-06 2017-03-22 Scott Dorfner Antibiotic formulations providing reduced gastrointestinal side effects and clostridium difficile infection relapse, and related methods
JP2013510900A (ja) * 2009-11-17 2013-03-28 ピラマル・ライフ・サイエンシーズ・リミテッド 炎症性疾患治療のための大環状ラクトン誘導体の使用
CA2785658C (en) * 2009-12-31 2017-10-24 Ira Milton Trachtman Compositions and method for treatment and prophylaxis of inflammatory bowel disease
CA2799386A1 (en) * 2010-05-18 2011-11-24 Optimer Pharmaceuticals, Inc. Treatment of clostridium difficile infection in patients undergoing antibiotic therapy
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CA2948400A1 (en) * 2014-05-09 2015-11-12 Astellas Pharma Europe Ltd Treatment regimen tiacumicin compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5443841A (en) 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US20070105791A1 (en) * 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
CA2494742C (en) * 2002-07-29 2015-05-12 Optimer Pharmaceuticals, Inc. Tiacumicin production
US7906489B2 (en) * 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
ZA200905337B (en) * 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
EP2070530B1 (en) 2016-02-17
PL2305244T3 (pl) 2017-04-28
US20130274175A1 (en) 2013-10-17
DK2305245T3 (en) 2019-03-25
EP2305245A1 (en) 2011-04-06
JP2012197309A (ja) 2012-10-18
EP1765312A4 (en) 2007-08-22
WO2005112990A3 (en) 2006-01-05
CA2566687C (en) 2012-07-24
PT2305244T (pt) 2016-12-29
PT2305245T (pt) 2019-03-19
WO2005112990A2 (en) 2005-12-01
TR201902533T4 (tr) 2019-03-21
EP2305244B1 (en) 2016-10-12
ES2608046T3 (es) 2017-04-05
CY1117501T1 (el) 2017-04-26
JP2007537290A (ja) 2007-12-20
JP6101010B2 (ja) 2017-03-22
BRPI0511119A (pt) 2007-11-27
EP1765312B1 (en) 2011-07-13
CY1121284T1 (el) 2020-05-29
SI2070530T1 (sl) 2016-05-31
HUE027757T2 (en) 2016-11-28
EP1765312A2 (en) 2007-03-28
LT2305245T (lt) 2019-03-12
ES2713954T3 (es) 2019-05-24
ES2565609T3 (es) 2016-04-05
EP2305245B1 (en) 2019-01-02
MX344601B (es) 2016-12-20
HUE031581T2 (en) 2017-07-28
DK2305244T3 (en) 2017-01-30
ATE516024T1 (de) 2011-07-15
PL2070530T3 (pl) 2016-06-30
SI2305245T1 (sl) 2019-04-30
DK2070530T3 (da) 2016-05-17
ES2395404T3 (es) 2013-02-12
EP2305244A1 (en) 2011-04-06
JP5734545B2 (ja) 2015-06-17
PL2305245T3 (pl) 2019-05-31
US20070173462A1 (en) 2007-07-26
CA2776682A1 (en) 2005-12-01
HUE043945T2 (hu) 2019-09-30
EP2070530A1 (en) 2009-06-17
CA2566687A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
MX344601B (es) Tratamiento de enfermedades asociadas con el uso de antibioticos.
MX2009007730A (es) Polimorfos macrocilicos, composiciones que comprenden tales polimorfos, y metodos para su uso y fabricacion.
EP4282489A3 (en) Treatment of clostridium difficile infection
TW200734344A (en) Antibacterial agents
CO2018011701A2 (es) Formulaciones de antibióticos glicopeptídicos estabilizados
WO2004017925A3 (en) Methods and reagents for preventing bacteremias
SG153833A1 (en) Methods of treatment of endobronchial infections
CO2019011264A2 (es) Nanosistemas que comprenden plata y antibióticos y su uso para el tratamiento de infecciones bacterianas
MX2022000233A (es) Inhibidores de deteccion de quórum y/o metabolitos posbióticos y métodos relacionados.
MX2022005256A (es) Inhibidores de cd73.
NZ545472A (en) 7-(4-substituted-3-cyclopropylaminomethyl-1-pyrrolidinyl)quinolonecarboxylic acid derivative
MX2021005740A (es) Novedoso compuesto como inhibidor de proteina quinasa, y composicion farmaceutica que comprende el mismo.
MX2018011046A (es) Composiciones y metodos para tratar canceres.
IN2014CN02908A (es)
PH12021551058A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
WO2009001192A3 (en) Novel compounds and their use
WO2017040762A3 (en) Methods for identifying novel antibiotics and related compositions
MX2021011469A (es) Combinacion de lisina(s) y antibiotico(s) para tratar o prevenir endocarditis infecciosa debida a bacterias gram-positivas.
MX2021013833A (es) Metodos y composiciones que comprenden variantes de la proteina a de estafilococos (spa).
WO2010131865A3 (ko) 항생제 내성 균주에 대한 항균용 조성물
IN2012DN00740A (es)
EP4026271A4 (en) HUMAN-READABLE AND MACHINE-READABLE CRYPTOGRAPHIC KEYS, OBTAINED FROM DICE
MX2018008192A (es) Compuestos derivados pirimido-isoquinolin-quinonas, sus sales, isomeros, tautomeros farmaceuticamente aceptables; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de enfermedades bacterianas y bacterianas multirresistentes.
WO2003068791A3 (en) Macrolides with activity against methicillin-resistant staphylococcus aureus
Benu Dhawan et al. Decreased susceptibility to vancomycin in methicillin-resistant Staphylococcus aureus: a 5 year study in an Indian tertiary hospital.

Legal Events

Date Code Title Description
FG Grant or registration